Oncogenic mutations of ALK kinase in neuroblastoma (original) (raw)

Nature volume 455, pages 971–974 (2008)Cite this article

Abstract

Neuroblastoma in advanced stages is one of the most intractable paediatric cancers, even with recent therapeutic advances1. Neuroblastoma harbours a variety of genetic changes, including a high frequency of MYCN amplification, loss of heterozygosity at 1p36 and 11q, and gain of genetic material from 17q, all of which have been implicated in the pathogenesis of neuroblastoma2,3,4,5. However, the scarcity of reliable molecular targets has hampered the development of effective therapeutic agents targeting neuroblastoma. Here we show that the anaplastic lymphoma kinase (ALK), originally identified as a fusion kinase in a subtype of non-Hodgkin’s lymphoma (NPM–ALK)6,7,8 and more recently in adenocarcinoma of lung (EML4–ALK)9,10, is also a frequent target of genetic alteration in advanced neuroblastoma. According to our genome-wide scans of genetic lesions in 215 primary neuroblastoma samples using high-density single-nucleotide polymorphism genotyping microarrays11,12,13,14, the ALK locus, centromeric to the MYCN locus, was identified as a recurrent target of copy number gain and gene amplification. Furthermore, DNA sequencing of ALK revealed eight novel missense mutations in 13 out of 215 (6.1%) fresh tumours and 8 out of 24 (33%) neuroblastoma-derived cell lines. All but one mutation in the primary samples (12 out of 13) were found in stages 3–4 of the disease and were harboured in the kinase domain. The mutated kinases were autophosphorylated and displayed increased kinase activity compared with the wild-type kinase. They were able to transform NIH3T3 fibroblasts as shown by their colony formation ability in soft agar and their capacity to form tumours in nude mice. Furthermore, we demonstrate that downregulation of ALK through RNA interference suppresses proliferation of neuroblastoma cells harbouring mutated ALK. We anticipate that our findings will provide new insights into the pathogenesis of advanced neuroblastoma and that _ALK_-specific kinase inhibitors might improve its clinical outcome.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Accession codes

Primary accessions

GenBank/EMBL/DDBJ

Data deposits

The nucleotide sequences of ALK mutations detected in this study have been deposited in GenBank under the accession numbers EU788003 (K1062M), EU788004 (T1087I), EU788005 (F1174L; TTC/TTA), EU788006 (F1174L; TTC/TTG), EU788007 (F1174C), EU788008 (F1174V), EU788009 (F1245L) and EU788010 (R1275Q). The copy number data as well as the raw microarray data will be accessible from http://www.ncbi.nlm.nih.gov/geo/ with the accession number GSE12494.

References

  1. Maris, J. M., Hogarty, M. D., Bagatell, R. & Cohn, S. L. Neuroblastoma. Lancet 369, 2106–2120 (2007)
    Article CAS Google Scholar
  2. Maris, J. M. et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children’s Cancer Group study. J. Clin. Oncol. 18, 1888–1899 (2000)
    Article CAS Google Scholar
  3. Attiyeh, E. F. et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 353, 2243–2253 (2005)
    Article CAS Google Scholar
  4. Bown, N. et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med. 340, 1954–1961 (1999)
    Article CAS Google Scholar
  5. Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E. & Bishop, J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224, 1121–1124 (1984)
    Article ADS CAS Google Scholar
  6. Shiota, M. et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 86, 1954–1960 (1995)
    CAS PubMed Google Scholar
  7. Morris, S. W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263, 1281–1284 (1994)
    Article ADS CAS Google Scholar
  8. Fujimoto, J. et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc. Natl Acad. Sci. USA 93, 4181–4186 (1996)
    Article ADS CAS Google Scholar
  9. Soda, M. et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007)
    Article ADS CAS Google Scholar
  10. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190–1203 (2007)
    Article CAS Google Scholar
  11. Kennedy, G. C. et al. Large-scale genotyping of complex DNA. Nature Biotechnol. 21, 1233–1237 (2003)
    Article CAS Google Scholar
  12. Matsuzaki, H. et al. Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. Nature Methods 1, 109–111 (2004)
    Article CAS Google Scholar
  13. Nannya, Y. et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res. 65, 6071–6079 (2005)
    Article CAS Google Scholar
  14. Yamamoto, G. et al. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am. J. Hum. Genet. 81, 114–126 (2007)
    Article CAS Google Scholar
  15. Osajima-Hakomori, Y. et al. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am. J. Pathol. 167, 213–222 (2005)
    Article CAS Google Scholar
  16. Donohoe, E. Denaturing high-performance liquid chromatography using the WAVE DNA fragment analysis system. Methods Mol. Med. 108, 173–187 (2005)
    CAS PubMed Google Scholar
  17. Hu, J., Liu, J., Ghirlando, R., Saltiel, A. R. & Hubbard, S. R. Structural basis for recruitment of the adaptor protein APS to the activated insulin receptor. Mol. Cell 12, 1379–1389 (2003)
    Article CAS Google Scholar
  18. Donella-Deana, A. et al. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry 44, 8533–8542 (2005)
    Article CAS Google Scholar
  19. McDermott, U. et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 68, 3389–3395 (2008)
    Article CAS Google Scholar
  20. Garraway, L. A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117–122 (2005)
    Article ADS CAS Google Scholar
  21. Mullighan, C. G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758–764 (2007)
    Article ADS CAS Google Scholar
  22. Kawamata, N. et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 111, 776–784 (2008)
    Article CAS Google Scholar
  23. Smith, E. I., Haase, G. M., Seeger, R. C. & Brodeur, G. M. A surgical perspective on the current staging in neuroblastoma—the International Neuroblastoma Staging System proposal. J. Pediatr. Surg. 24, 386–390 (1989)
    Article CAS Google Scholar
  24. Takita, J. et al. Allelotype of neuroblastoma. Oncogene 11, 1829–1834 (1995)
    CAS PubMed Google Scholar
  25. Takita, J. et al. Absent or reduced expression of the caspase 8 gene occurs frequently in neuroblastoma, but not commonly in Ewing sarcoma or rhabdomyosarcoma. Med. Pediatr. Oncol. 35, 541–543 (2000)
    Article CAS Google Scholar
  26. Takita, J. et al. Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma. Oncogene 20, 4424–4432 (2001)
    Article CAS Google Scholar

Download references

Acknowledgements

We thank H. P. Koeffler for critically reading and editing the manuscript. We also thank M. Matsumura, Y. Ogino, S. Ichimura, S. Sohma, E. Matsui, Y. Yin, N. Hoshino and Y. Nakamura for their technical assistance. This work was supported by the Core Research for Evolutional Science and Technology, Japan Science and Technology Agency and by a Grant-in-Aid from the Ministry of Health, Labor and Welfare of Japan for the third-term Comprehensive 10-year Strategy for Cancer Control.

Author Contributions Y.C., Y.L.C. and J.T. contributed equally to this work. M.K. and M.Sa. performed microarray experiments and subsequent data analyses. Y.C. and J.T. performed mutation analysis of ALK. Y.C., Y.L.C., J.T., M.So., L.W. and H.M. conducted functional assays of mutant ALK. A.N., M.O., T.I., A.K. and Y.H. prepared tumour specimens and were involved in statistical analysis. A.N., Y.H., H.M., J.T. and S.O. designed the overall study, and S.O. and J.T. wrote the manuscript. All authors discussed the results and commented on the manuscript.

Author information

Author notes

  1. Yuyan Chen, Junko Takita and Young Lim Choi: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Pediatrics,,
    Yuyan Chen, Junko Takita, Motohiro Kato & Takashi Igarashi
  2. Cell Therapy and Transplantation Medicine,,
    Yuyan Chen, Junko Takita, Masashi Sanada, Lili Wang & Seishi Ogawa
  3. Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan ,
    Yuyan Chen, Junko Takita, Motohiro Kato, Masashi Sanada, Lili Wang & Seishi Ogawa
  4. Division of Functional Genomics, Jichi Medical University, Toguchi 329-0498, Japan
    Young Lim Choi, Manabu Soda & Hiroyuki Mano
  5. Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan
    Miki Ohira & Akira Nakagawara
  6. Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Saitama, 332-0012, Japan
    Masashi Sanada, Lili Wang, Hiroyuki Mano & Seishi Ogawa
  7. Division of Hematology/Oncology, Saitama Children’s Medical Center, Saitama 339-8551, Japan
    Akira Kikuchi
  8. Gunma Children’s Medical Center, Shibukawa 377-8577, Japan
    Yasuhide Hayashi

Authors

  1. Yuyan Chen
    You can also search for this author inPubMed Google Scholar
  2. Junko Takita
    You can also search for this author inPubMed Google Scholar
  3. Young Lim Choi
    You can also search for this author inPubMed Google Scholar
  4. Motohiro Kato
    You can also search for this author inPubMed Google Scholar
  5. Miki Ohira
    You can also search for this author inPubMed Google Scholar
  6. Masashi Sanada
    You can also search for this author inPubMed Google Scholar
  7. Lili Wang
    You can also search for this author inPubMed Google Scholar
  8. Manabu Soda
    You can also search for this author inPubMed Google Scholar
  9. Akira Kikuchi
    You can also search for this author inPubMed Google Scholar
  10. Takashi Igarashi
    You can also search for this author inPubMed Google Scholar
  11. Akira Nakagawara
    You can also search for this author inPubMed Google Scholar
  12. Yasuhide Hayashi
    You can also search for this author inPubMed Google Scholar
  13. Hiroyuki Mano
    You can also search for this author inPubMed Google Scholar
  14. Seishi Ogawa
    You can also search for this author inPubMed Google Scholar

Corresponding authors

Correspondence toYasuhide Hayashi or Seishi Ogawa.

Supplementary information

Supplementary Information

This file contains Supplementary Tables 1-7 and Supplementary Figures 1-11 with Legends (PDF 4451 kb)

PowerPoint slides

Rights and permissions

About this article

Cite this article

Chen, Y., Takita, J., Choi, Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma.Nature 455, 971–974 (2008). https://doi.org/10.1038/nature07399

Download citation

This article is cited by

Editorial Summary

Neuroblastoma is the most common childhood cancer. There is a strong familial association and it was predicted over 30 years ago that there was a genetic element to the disease. Four groups now report the identification of mutations in the tyrosine kinase receptor ALK (anaplastic lymphoma kinase) in neuroblastoma patients. ALK acts as a neuroblastoma predisposition gene, and somatic point mutations occur in sporadic neuroblastoma cases. These mutations promote ALK's kinase activity and can transform cells and display tumorigenic activity in vivo. ALK inhibitors decrease neuroblastoma cell proliferation, so have potential as anticancer drugs.

Associated content